GlassScriptPhysician profile
Charles A Gerk
NPI 1194992768
$20,583.68
in general payments reported to CMS, 2019-2025
22 companies · $302 in 2025
The $302 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,658 · 2020: $3,627 · 2021: $282 · 2022: $3,068 · 2023: $4,413 · 2024: $233 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,096 · Food and Beverage: $853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,096.00 |
| Food and Beverage | $852.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $7,131.01 | 2019-2025 | Breztri, Farxiga |
| Glaxosmithkline, LLC. | $4,933.44 | 2019-2024 | Trelegy Ellipta |
| Midmark Corporation | $4,278.17 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $2,800.00 | 2020 | |
| Lilly USA, LLC | $421.09 | 2019-2025 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $181.18 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $131.04 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $129.56 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $119.62 | 2019-2024 | Vaxelis, M-M-R II, Gardasil 9 |
| Pfizer INC. | $82.61 | 2021-2022 | |
| Abbvie INC. | $72.40 | 2021-2023 | |
| Sanofi Pasteur INC. | $62.27 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $35.06 | 2022 | |
| Amgen INC. | $30.51 | 2025 | Prolia, Evenity |
| Sanofi-Aventis U.S. LLC | $28.46 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $23.94 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $22.29 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.02 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $20.29 | 2019 | |
| Radius Health, INC. | $19.58 | 2025 | Tymlos |
| Inspire Medical Systems, INC. | $17.44 | 2025 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Gerk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.